Biogen’s Q3 Aduhelm Sales Even Worse Than Expected
Executives Emphasize Low Expectations Through Year-End
Executive Summary
Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.
You may also be interested in...
Biogen Resets Aduhelm Expectations, Expects Longer, Slower Path To Significant Sales
The company reported $1m in Q4 sales of its Alzheimer’s drug. Biogen expects Aduhelm to make a minimal contribution to full-year 2022 revenues, which will total about $1bn less than in 2021.
Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm
The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.
J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals
Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals.